Integrated Biopharma, Inc.
INBP
$0.3069
$0.01194.03%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 12.61M | 13.62M | 12.75M | 13.15M | 11.51M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.61M | 13.62M | 12.75M | 13.15M | 11.51M |
| Cost of Revenue | 11.44M | 12.25M | 11.46M | 11.90M | 10.99M |
| Gross Profit | 1.17M | 1.37M | 1.28M | 1.25M | 520.00K |
| SG&A Expenses | 969.00K | 881.00K | 882.00K | 893.00K | 972.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.41M | 13.13M | 12.34M | 12.79M | 11.96M |
| Operating Income | 202.00K | 490.00K | 402.00K | 355.00K | -452.00K |
| Income Before Tax | 185.00K | 504.00K | 414.00K | 352.00K | -452.00K |
| Income Tax Expenses | 69.00K | 245.00K | 146.00K | 67.00K | -70.00K |
| Earnings from Continuing Operations | 116.00K | 259.00K | 268.00K | 285.00K | -382.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 116.00K | 259.00K | 268.00K | 285.00K | -382.00K |
| EBIT | 202.00K | 490.00K | 402.00K | 355.00K | -452.00K |
| EBITDA | 285.00K | 578.00K | 489.00K | 432.00K | -374.00K |
| EPS Basic | 0.00 | 0.01 | 0.01 | 0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.01 | 0.01 | 0.01 | -0.01 |
| EPS Diluted | 0.00 | 0.01 | 0.01 | 0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.01 | 0.01 | 0.01 | -0.01 |
| Average Basic Shares Outstanding | 30.17M | 30.10M | 30.10M | 30.10M | 30.10M |
| Average Diluted Shares Outstanding | 31.30M | 30.65M | 30.70M | 30.76M | 30.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
